Compounds > tris(1,3-dichloro-2-propyl)phosphate

Page last updated: 2024-12-06

tris(1,3-dichloro-2-propyl)phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	26177
CHEMBL ID	3182032
CHEBI ID	143729
SCHEMBL ID	333198
MeSH ID	M0067025

Synonyms (70)

Synonym
tris[2-chloro-1-(chloromethyl)ethyl] phosphate
13674-87-8
tris-(1,3-dichloro-2-propyl)phosphate
tris(1,3-dichloroisopropyl)phosphate
fyrol fr 2
inchi=1/c9h15cl6o4p/c10-1-7(2-11)17-20(16,18-8(3-12)4-13)19-9(5-14)6-15/h7-9h,1-6h
crp (fireproofing agent)
tris(1-chloromethyl-2-chloroethyl)phosphate
tris(2-chloro-1-(chloromethyl)ethyl) phosphate
tri(beta,beta'-dichloroisopropyl)phosphate
pf 38/3
einecs 237-159-2
fyrol fr-2
ccris 6284
tdcpp
tris(1,3-dichloro-2-propyl)phosphate
emulsion 212
1,3-dichloro-2-propanol phosphate (3:1)
fosforan troj-(1,3-dwuchloroizopropylowy) [polish]
pf 38
brn 1715458
hsdb 4364
tris(2-chloro-1-(chloromethyl)ethyl)phosphate
CRP ,
2-propanol, 1,3-dichloro-, phosphate (3:1)
tris(1,3-dichloro-2-propyl) phosphate
phosphoric acid tris(1,3-dichloro-2-propyl) ester
FT-0654115
P0269
tris(1,3-dichloropropan-2-yl) phosphate
CHEBI:143729
A807122
tris(1,3-dichloro-2-propyl) phosphate;tris(1,3-dichloro-2-propyl)phosphate
NCGC00247923-01
NCGC00247923-02
3-01-00-01473 (beilstein handbook reference)
b1prv4g0t0 ,
unii-b1prv4g0t0
fosforan troj-(1,3-dwuchloroizopropylowy)
ec 237-159-2
2-propanol, 1,3-dichloro-, 2,2',2''-phosphate
tox21_300194
NCGC00254047-01
NCGC00259715-01
dtxsid9026261 ,
tox21_202166
cas-13674-87-8
dtxcid206261
tdcipp
S12389
AKOS015856734
tris(1,3-dichloro-2-propyl)phosphate [hsdb]
tdcpp [mi]
SCHEMBL333198
phosphoric acid tris(1,3-dichloro-2-propyl)ester
tri(.beta.,.beta.'-dichloroisopropyl)phosphate
tris[2-chloro-1-(chloromethyl)ethyl] phosphate #
ASLWPAWFJZFCKF-UHFFFAOYSA-N
HY-108712
CS-8011
CHEMBL3182032
tris(1,3-dichloro-2-propyl) phosphate, 95%
mfcd00083121
tdcpp, analytical standard
J-006902
tris(1.3-dichloro-2-propyl) phosphate
phosphoric acid tris-(2-chloro-1-chloromethyl-ethyl) ester
Q2454085
tris-(1,3-dichloroisopropyl) phosphate standard 50 microg/ml in acetonitrile
fyrol fr 2,tcpp

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" TDCPP was toxic to hepatocytes (LC₅₀ = 60."	( Effects of tris(1,3-dichloro-2-propyl) phosphate and tris(1-chloropropyl) phosphate on cytotoxicity and mRNA expression in primary cultures of avian hepatocytes and neuronal cells. Chiu, S; Crump, D; Kennedy, SW, 2012)	0.38
"Tris(1,3-dichloro-2-propyl) phosphate (TDCIPP) has been frequently detected in environmental media and has adverse health effect on wildlife and humans."	( Acute Exposure to Tris(1,3-dichloro-2-propyl) Phosphate (TDCIPP) Causes Hepatic Inflammation and Leads to Hepatotoxicity in Zebrafish. Agrawal, I; Giesy, JP; Gong, Z; Letcher, RJ; Li, G; Li, J; Liu, C; Su, G; Wang, J; Yu, L, 2016)	0.43
" Due to the hazardous effects of many of these chemicals, manufacturers are developing next generation potential less toxic alternatives."	( Acute mixture toxicity of halogenated chemicals and their next generation counterparts on zebrafish embryos. Abdel-Moneim, A; Godfrey, A; Sepúlveda, MS, 2017)	0.46
" Developmental toxicity is a major concern of OPFRs' adverse health effects."	( Exposure to tris(1,3-dichloro-2-propyl) phosphate (TDCPP) induces vascular toxicity through Nrf2-VEGF pathway in zebrafish and human umbilical vein endothelial cells. Kang, J; Qiu, J; Shi, X; Wei, Y; Xing, X; Zhong, X, 2019)	0.51
"As the application and environmental release of tris(1,3-dichloro-2-propyl) phosphate (TDCIPP) are being increased rapidly, serious concerns have been raised regarding its adverse effects on human health."	( Sub-chronic exposure to Tris(1,3-dichloro-2-propyl) phosphate induces sex-dependent hepatotoxicity in rats. Hu, X; Li, X; Wang, S, 2019)	0.51
" The ubiquitous distribution and persistence of TDCPP in aquatic environment have led to concerns over its possible toxic effects on aquatic organism."	( Toxic effect and mechanism of tris (1,3-dichloro-2-propyl)phosphate (TDCPP) on the marine alga Phaeodactylum tricornutum. Jian, X; Liu, Q; Ma, W; Tang, X; Wang, Y; Yang, Y; Zhang, X, 2020)	0.56
"Humans are exposed to many xenobiotics simultaneously, but little is known about the toxic effects based on chemical-chemical interactions."	( Impact of Mixture Effects between Emerging Organic Contaminants on Cytotoxicity: A Systems Biological Understanding of Synergism between Tris(1,3-dichloro-2-propyl)phosphate and Triphenyl Phosphate. Chen, D; Cheng, HS; Fang, M; Jia, S; Koh, D; Liu, M; Peng, B; Tan, NS; Wang, Y; Warth, B; Zhang, Y, 2020)	0.76
" The DEPs associated with toxic effects of TDCIPP were then screened by use of Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes for enrichment analysis."	( Proteomic analysis using isobaric tags for relative and absolute quantification technology reveals mechanisms of toxic effects of tris (1,3-dichloro-2-propyl) phosphate on RAW264.7 macrophage cells. Giesy, JP; Wang, P; Wang, R; Wei, S; Zhang, S; Zhang, W, 2022)	0.72

Bioavailability

Excerpt	Reference	Relevance
" Microplastics (plastic particles < 5 mm) and nanoplastics (plastic particles < 100 nm) can interact with organic pollutants already present in the aquatic environment, potentially acting as carriers for pollutants entering organisms and thus influencing the bioavailability and toxicity of those pollutants."	( Parental transfer of nanopolystyrene-enhanced tris(1,3-dichloro-2-propyl) phosphate induces transgenerational thyroid disruption in zebrafish. Duan, X; Liu, Z; Ren, X; Zhao, X, 2021)	0.62

Dosage Studied

Excerpt	Relevance	Reference
" Dermal uptake and percutaneous penetration of the OPEs were studied in a Franz diffusion cell system using human skin dosed with a mixture of OPEs in an ethanol:toluene (4:1) solution."	( Dermal uptake and percutaneous penetration of organophosphate esters in a human skin ex vivo model. Clausen, PA; Frederiksen, M; Jensen, NM; Knudsen, LE; Nielsen, F; Nielsen, JB; Stapleton, HM; Sørensen, JA; Sørensen, LS; Vorkamp, K; Webster, TF, 2018)	0.48
" Exposure to TDCPP resulted in a dose-response decrease of micoalgal biomass."	( Metabolomics reveals that tris(1,3-dichloro-2-propyl)phosphate (TDCPP) causes disruption of membrane lipids in microalga Scenedesmus obliquus. Huang, X; Laserna, AKC; Li, SFY; Wang, L, 2020)	0.86

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
trialkyl phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	27.4253	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
GLI family zinc finger 3	Homo sapiens (human)	Potency	1.4422	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	41.4775	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	61.3618	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	40.6851	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	7.2600	0.0004	17.9460	75.1148	AID1346795
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	13.6181	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	40.8340	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	16.4201	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	50.9394	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	49.0007	0.3758	27.4851	61.6524	AID743217; AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	20.1573	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	44.1618	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	43.6412	0.0010	19.4141	70.9645	AID743191
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	61.3977	0.0017	23.8393	78.1014	AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	7.1144	0.0578	21.1097	61.2679	AID1159526; AID1159528
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	11.2454	0.0391	47.5451	146.8240	AID1224845
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	64.6858	0.0003	23.4451	159.6830	AID743065; AID743067
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	61.3618	0.0015	57.7890	15,848.9004	AID1259244
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	61.3618	0.0015	51.7393	15,848.9004	AID1259244
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	68.2410	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	68.2410	0.0119	12.2221	68.7989	AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Process	via Protein(s)	Taxonomy
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Process	via Protein(s)	Taxonomy
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Process	via Protein(s)	Taxonomy
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (87)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (10.34)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (3.45)	29.6817
2010's	59 (67.82)	24.3611
2020's	16 (18.39)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	30.62 (24.57)
Research Supply Index	4.50 (2.92)
Research Growth Index	5.85 (4.65)
Search Engine Demand Index	38.54 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (30.62)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (2.25%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	87 (97.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
cytosine [no description available]	7.21	1	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
chlorpyrifos Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.	2.13	1	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	2.51	2	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	2.58	2	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	4.96	8	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
triethyl phosphate triethyl phosphate: structure. triethyl phosphate : A trialkyl phosphate that is the triethy ester derivative of phosphoric acid.	2.13	1	trialkyl phosphate
tris(2-butoxyethyl) phosphate tris(2-butoxyethyl) phosphate: inhibitor of drug-protein binding; present in stoppers of blood sample 'vacutainers'. tris(2-butoxyethyl) phosphate : A trialkyl phosphate in which the alkyl group specified is 2-butoxyethyl.	3.04	4	trialkyl phosphate	environmental contaminant; flame retardant
tetrabromobisphenol a tetrabromobisphenol A: a brominated flame retardant. 3,3',5,5'-tetrabromobisphenol A : A bromobisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups and the phenyl rings are substituted by bromo groups at positions 2, 2', 6 and 6'. It is a brominated flame retardant.	3.05	4	brominated flame retardant; bromobisphenol
triphenyl phosphite [no description available]	2.97	1
acrolein [no description available]	1.95	1	enal	herbicide; human xenobiotic metabolite; toxin
triphenyl phosphate triphenyl phosphate: structure. triphenyl phosphate : An aryl phosphate resulting from the formal condensation of phosphoric acid with 3 mol eq. of phenol.	9.82	11	aryl phosphate	flame retardant; plasticiser
tris(chloroethyl)phosphate tris(chloroethyl)phosphate: has gonadotoxic effects. tris(2-chloroethyl) phosphate : A trialkyl phosphate that is the tris(2-chloroethyl) ester of phosphoric acid.	2.41	1	organochlorine compound; trialkyl phosphate
perfluorooctanoic acid perfluorooctanoic acid: RN given refers to parent cpd. perfluorooctanoic acid : A fluoroalkanoic acid that is perfluorinated octanoic acid.	2.55	2	fluoroalkanoic acid	carcinogenic agent; endocrine disruptor; environmental contaminant; surfactant; xenobiotic
perfluorobutyric acid perfluorobutyric acid: ion pairing reagent; RN given refers to parent cpd. perfluorobutyric acid : A monocarboxylic acid that is perfluorinated butyric acid.	2.15	1	fluoroalkanoic acid	chromatographic reagent; environmental contaminant; xenobiotic
decabromobiphenyl ether decabromobiphenyl ether: a flame retardant. decabromodiphenyl ether : A polybromodiphenyl ether that is diphenyl ether in which all of the hydrogens have been replaced by bromines.	2	1	polybromodiphenyl ether	neurotoxin
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	2.17	1	diatomic chlorine; gas molecular entity	bleaching agent
dechlorane plus dechlorane plus: a flame retardant; structure in first source	2.17	1
tri-(2-chloroisopropyl)phosphate [no description available]	2.82	3	trialkyl phosphate
tris(2,3-dibromopropyl)phosphate tris(2,3-dibromopropyl)phosphate: flame retardant	4.88	11	trialkyl phosphate
2,2',4,4'-tetrabromodiphenyl ether [no description available]	2.55	2	aromatic ether; organobromine compound
phosphites Phosphites: Inorganic salts or organic esters of phosphorous acid that contain the (3-)PO3 radical. (From Grant & Hackh's Chemical Dictionary, 5th ed). phosphite(3-) : A trivalent inorganic anion obtained by removal of all three protons from phosphorous acid.	2.97	1	phosphite ion; trivalent inorganic anion
caprylates Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis.	2.55	2	fatty acid anion 8:0; straight-chain saturated fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
tris(2-carboxyethyl)phosphine tris(2-carboxyethyl)phosphine: water-soluble reagent which irreversibly reduces disulfides to thiols at room temperature & is active below neutral pH; used for quantitation of iodine and iodate. TCEP : A tertiary phosphine in which phosphane is substituted with three 2-carboxyethyl groups. It is a commonly used reducing agent.	3.37	6	phosphine derivative; tricarboxylic acid	reducing agent
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	3	1	divalent inorganic anion; phosphite ion
nadp [no description available]	1.96	1
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.31	1
11-ketotestosterone 11-ketotestosterone: RN given refers to cpd without isomeric designation. 11-oxotestosterone : A 3-oxo Delta(4)-steroid that is testosterone carrying an additional oxo substituent at position 11.	2.11	1	11-oxo steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; human metabolite; marine xenobiotic metabolite
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	2.21	1	4-hydroxynon-2-enal; 4-hydroxynonenal
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	2.17	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
diphenyl phosphite diphenyl phosphite: a coupling agent for making sterically hindered peptide analogs; structure in first source	3	1
2-ethylhexyl 2,3,4,5-tetrabromobenzoate 2-ethylhexyl 2,3,4,5-tetrabromobenzoate: structure in first source	2.15	1
tetracarboxyphenylporphine [no description available]	2.46	2
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	2.15	1

Condition	Relationship Strength	Studies
Interstitial Cell Tumor [description not available]	2.41	1
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	3.52	4
Diabetes Mellitus, Adult-Onset [description not available]	3.52	4
Insulin Sensitivity [description not available]	3.52	4
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	3.52	4
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	3.52	4
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	3.52	4
Acute Liver Injury, Drug-Induced [description not available]	2.57	2
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.57	2
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.42	2
Encephalopathy, Toxic [description not available]	2.85	3
Innate Inflammatory Response [description not available]	2.58	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.58	2
Asthma, Bronchial [description not available]	2.31	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	7.31	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.84	3
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.21	1
Cirrhosis [description not available]	2.1	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.1	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.4	2
Abnormalities, Autosome [description not available]	1.95	1
Germinoblastoma [description not available]	1.95	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	1.95	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.96	1

chemdatabank.com